Semaglutide vs Tirzepatide vs Retatrutide: Complete Comparison

The GLP-1 Revolution

The development of GLP-1 receptor agonists represents one of the most significant breakthroughs in metabolic medicine in decades. What began as a diabetes treatment has become the most effective pharmacological approach to weight loss ever documented in clinical trials.

But the field has evolved rapidly. Semaglutide was the first blockbuster, followed by Tirzepatide's dual-mechanism approach, and now Retatrutide's triple-agonist design. Understanding the differences is critical for choosing the right compound.

Head-to-Head Comparison

Feature	Semaglutide	Tirzepatide	Retatrutide
Brand names	Ozempic, Wegovy, Rybelsus	Mounjaro, Zepbound	Investigational (Phase III)
Receptor targets	GLP-1 only	GLP-1 + GIP	GLP-1 + GIP + Glucagon
Mechanism type	Single agonist	Dual agonist	Triple agonist
Key trial programme	STEP (weight), SUSTAIN (diabetes)	SURMOUNT (weight), SURPASS (diabetes)	Phase II (NEJM 2023)
Average weight loss (max dose)	~15–17%	~22.5%	~24.2%
Trial duration	68 weeks (STEP 1)	72 weeks (SURMOUNT-1)	48 weeks (Phase II)
Dosing frequency	Once weekly	Once weekly	Once weekly
Max studied dose	2.4 mg (Wegovy)	15 mg (Zepbound)	12 mg (Phase II)
FDA-approved (weight loss)	Yes (Wegovy, 2021)	Yes (Zepbound, 2023)	Not yet (Phase III ongoing)
GI side effect rate	~40–45% (mostly mild/moderate)	~25–35% (with proper titration)	~35–45% (Phase II data)
Cardiovascular data	SELECT trial: 20% MACE reduction	SURPASS-CVOT ongoing	Not yet studied

Deep Dive: Semaglutide

Semaglutide is the compound that started the obesity pharmacotherapy revolution. Developed by Novo Nordisk, it's a modified GLP-1 analogue with a fatty acid sidechain that extends its half-life to approximately 7 days, enabling once-weekly dosing.

Mechanism

Semaglutide activates the GLP-1 receptor, which is expressed in:

• Pancreatic beta cells — enhances insulin secretion in a glucose-dependent manner
• Hypothalamus — suppresses appetite via POMC neuron activation
• Gastrointestinal tract — slows gastric emptying
• Cardiovascular system — anti-inflammatory and cardioprotective effects

Clinical Data

The STEP trial programme demonstrated:

• STEP 1: 14.9% weight loss vs 2.4% placebo at 68 weeks (non-diabetic adults)
• STEP 2: 9.6% weight loss in type 2 diabetes patients
• STEP 3: 16.0% when combined with intensive behavioural therapy
• STEP 4: Continued weight loss vs. rapid regain in those switched to placebo

The SELECT cardiovascular outcomes trial showed a 20% reduction in major adverse cardiovascular events (MACE) — making Semaglutide the first obesity drug to demonstrate cardiovascular protection.

Titration Schedule

Week	Dose
1–4	0.25 mg
5–8	0.5 mg
9–12	1.0 mg
13–16	1.7 mg
17+	2.4 mg

Critical: Rushing the titration is the number-one cause of intolerable GI side effects. Be patient.

Deep Dive: Tirzepatide

Tirzepatide (Eli Lilly) was a paradigm shift — the first dual GIP/GLP-1 agonist. By targeting two incretin receptors simultaneously, it achieves greater weight loss with potentially better tolerability than single-receptor agonists.

Mechanism

Tirzepatide activates both:

• GLP-1 receptors — appetite suppression, gastric slowing, insulin secretion
• GIP receptors — enhanced fat metabolism, improved insulin sensitivity, potentiation of GLP-1 effects

The GIP receptor was previously misunderstood. Early research suggested blocking GIP might help with obesity. Tirzepatide proved the opposite — activating GIP alongside GLP-1 produces superior metabolic outcomes.

Clinical Data

The SURMOUNT programme delivered:

• SURMOUNT-1: 22.5% weight loss at 15 mg dose over 72 weeks — the highest ever recorded in a weight-loss drug trial at that time
• SURMOUNT-2: 14.7% in type 2 diabetes patients
• SURMOUNT-3: 26.6% when combined with intensive lifestyle intervention
• SURMOUNT-4: Maintained weight loss vs. rapid regain on placebo

Titration Schedule

Week	Dose
1–4	2.5 mg
5–8	5 mg
9–12	7.5 mg
13–16	10 mg
17–20	12.5 mg
21+	15 mg

Deep Dive: Retatrutide

Retatrutide is the next frontier — a triple agonist targeting GLP-1, GIP, and the glucagon receptor. Adding the glucagon receptor is what separates it from all predecessors.

Mechanism

In addition to GLP-1 and GIP effects, the glucagon receptor activation provides:

• Increased thermogenesis — glucagon directly stimulates energy expenditure
• Enhanced hepatic fat oxidation — glucagon is the primary signal for the liver to burn fat
• Liver fat reduction — Phase II data showed dramatic reductions in hepatic steatosis (fatty liver)

This three-pronged approach attacks obesity from appetite (GLP-1), metabolic efficiency (GIP), and energy expenditure (glucagon) — simultaneously.

Clinical Data

The Phase II trial published in the New England Journal of Medicine (2023) showed:

• 24.2% weight loss at the 12 mg dose over just 48 weeks
• At 24 weeks, participants were still on a steep weight-loss trajectory — meaning final numbers at 48 weeks would likely have been higher with continued treatment
• Significant reductions in liver fat, HbA1c, and triglycerides
• Side effect profile comparable to other GLP-1 agonists

Phase III trials are currently underway.

Titration Schedule (Phase II Protocol)

Week	Dose
1–4	0.5 mg
5–8	2 mg
9–12	4 mg
13–16	8 mg
17+	12 mg

Which One Should You Choose?

Choose Semaglutide If:

• You want a compound with the longest track record and most safety data
• Cardiovascular risk reduction is a priority (SELECT trial data)
• You're looking for the most extensively studied option
• Weight loss of 15–17% is sufficient for your goals

Choose Tirzepatide If:

• You want maximum currently-approved weight loss (~22.5%)
• You prefer a compound with potentially better GI tolerability
• You're interested in dual-receptor benefits (improved insulin sensitivity, enhanced fat metabolism)
• You have access to it and can afford it

Choose Retatrutide If:

• You're comfortable with a compound still in clinical trials (Phase III)
• You want the highest documented weight loss (~24.2% and likely higher at longer durations)
• Fatty liver is a concern (the glucagon component is uniquely effective here)
• You're interested in the added thermogenic effect

Managing Side Effects Across All Three

The most common side effects for all GLP-1 agonists are gastrointestinal:

• Nausea (most common, usually worst in first 2–4 weeks at each dose level)
• Constipation or diarrhoea
• Decreased appetite (usually a desired effect, but can be excessive)
• Acid reflux / GERD

Management strategies:

• Titrate slowly — never skip dose levels, even if you feel fine
• Eat smaller meals — your stomach empties more slowly now
• Stay hydrated — reduced food intake means less water from food
• Avoid high-fat, greasy meals — these exacerbate nausea
• Ginger tea or anti-nausea medication for the first week at each new dose
• Protein priority — ensure adequate protein intake (1.6–2.2 g/kg) to minimise muscle loss

The Titration Rule

This cannot be overstated: the single most important factor in tolerability is proper titration. Jumping straight to a high dose — or escalating too quickly — is the primary cause of severe side effects that lead people to discontinue treatment.

Every dose level needs a minimum of 4 weeks. Many people benefit from 6–8 weeks at each level. There is no rush. The weight will come off.

The Future

The trajectory is clear: from single to dual to triple agonism, with each generation producing greater weight loss and broader metabolic benefits. Compounds in earlier development are exploring quadruple agonists and even more complex receptor profiles.

But for now, these three compounds represent the cutting edge of metabolic pharmacotherapy — and they're all available in Bali through Mito Labs.